Pharma BD Deal Intelligence

Pharmstandard OJSC / Bever Pharmaceutical Pte Ltd

2013 · Acquisition/Merger · $590M · Complete

Announcement Sentiment

Negative

Pharmstandard acquired Singapore-based Bever Pharmaceutical for $590M ($542M equity + $48M cash) to secure long-term API supply for Arbidol and Aphobazolum OTC franchises.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Assessment window: 5yr post-close.

Key facts

Announced Aug 22, 2013
Closed Oct 31, 2013
Deal value $590M
Deal type Acquisition/Merger
Therapeutic area Antiviral (influenza), anxiolytic (Russia/CIS)
Indications Antiviral (influenza), anxiolytic (Russia/CIS)
Key assets API supply for Arbidol (umifenovir) and Aphobazolum
Mechanism Active pharmaceutical ingredient manufacturing

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals